PMD54 Resource Utilisation Related to Catheter-associated Urinary Tract infections in Swedish Spinal injury Patients  by Bruce, S. et al.
PMD49
THE POTENTIAL ROLE OF MAGNETIC RESONANCE IMAGING (MRI) IN AXILLARY
NODE ASSESSMENT OF EARLY BREAST CANCER: AN ECONOMIC EVALUATION
Meng Y1, Ward SE1, Cooper K1, Harnan SE1, Wyld L2
1University of Sheffield, Sheffield, UK, 2Royal Hallamshire Hospital, Sheffield, UK
OBJECTIVES: Surgical techniques including sentinel lymph node biopsy (SLNB) and
4-node sampling (4-NS) are currently used for axillary nodal assessment of early
breast cancer (EBC) in the UK. Such procedures are associated with adverse effects,
(AEs), in particular scarring, pain, general anaesthesia and occasional lymphoe-
dema which may impact on long term quality of life. Magnetic resonance imaging
(MRI) is a non-invasive technique offering the potential to avoid such AEs. A range
of MRI techniques, including USPIO (ultrasmall superparamagnetic iron oxide con-
trast agent)-enhanced and gadolinium-enhanced MRI exist, however diagnostic
accuracy of these techniques may be lower than for surgical techniques. An eco-
nomic evaluation was undertaken to compare MRI with surgical techniques for
assessment of axillary lymph node metastases in patients with EBC. METHODS:
The costs and benefits of replacing SLNB or 4-NS with MRI (replacement strategy) or
adding MRI before the surgical techniques (addition strategy) were modelled using
discrete-event simulation in SIMUL8®. A systematic review was undertaken to
obtain effectiveness outcomes of the MRI techniques, whilst resource use data and
health related utilities were obtained from the literature. RESULTS: Our results
predict that a replacement strategy for MRI, based on the pooled estimate of all MRI
techniques, dominates the baseline SLNB and 4-NS strategies, as a result of avoid-
ing AEs from surgical techniques. However this strategy leads to more false-posi-
tive and false-negative cases. The MRI addition strategy may also be cost-effective,
but is subject to greater uncertainty. USPIO-enhanced MRI produces the most fa-
vourable cost effectiveness ratio, but the evidence is based on studies with small
patient numbers. CONCLUSIONS: These results suggest that there is a potential
role for MRI in axillary node assessment of EBC. Based on current evidence USPIO-
enhanced MRI offers the most cost effective option, but further large studies are
required to obtain high quality evidence on diagnostic accuracy.
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COST-EFFECTIVENESS OF CARDIAC RESYNCHRONISATION THERAPY FOR
PATIENTS WITH MODERATE-TO-SEVERE HEART FAILURE
Neyt M, Stroobandt S, Obyn C, Camberlin C, Devriese S, De Laet C, Van Brabandt H
Belgian Health Care Knowledge Centre, Brussels, Belgium
OBJECTIVES:To assess the cost-effectiveness of cardiac resynchronisation therapy
(CRT) both with CRT-P (biventricular pacemaker only) and CRT-D (biventricular
pacemaker with defibrillator) in patients with New York Heart Association (NYHA)
functional class III/IV from a Belgian health care payer perspective. METHODS: A
lifetime Markov model was designed to calculate the cost-utility of both interven-
tions. In the reference case, the treatment effect is based on the COMPANION trial.
Costs are based on real-world data. Pharmacoeconomic guidelines were applied,
including probabilistic modelling and sensitivity analyses. RESULTS: Compared
with optimal medical treatment, on average 1.31 quality-adjusted life-years (QALY)
are gained with CRT-P at an additional cost of €14,700, resulting in an incremental
cost-effectiveness ratio (ICER) of about €11,200/QALY. As compared to CRT-P,
CRT-D treatment adds on average an additional 0.55 QALYs at an extra cost of
€30,900 resulting in an ICER of €57,000/QALY. This result was very sensitive to the
incremental clinical benefit of the defibrillator function on top of CRT.
CONCLUSIONS: Based on efficiency arguments, CRT-P can be recommended for
NYHA class III and IV patients if there is a willingness to pay more than €11,000/
QALY. Even though CRT-D may offer a survival benefit over CRT-P, the incremental
clinical benefit appears to be too marginal to warrant a three times higher device
price for CRT-D. Further clinical research should focus on the added value of CRT-D
over CRT-P.
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COST SAVINGS AND IMPROVED UTILITY THROUGH THE USE OF FLORBETABEN
BETA-AMYLOID PET IMAGING IN DEMENTIA DIAGNOSIS
Pastätter R1, Uhl-hochgräber K2, Blankenburg M2
1Karolinska Institute, Stockholm, Sweden, 2Bayer HealthCare Pharmaceuticals, Berlin, Germany
OBJECTIVES: Early diagnosis of Alzheimer’s disease may allow for early appropri-
ate treatment, delayed symptom aggravation, delayed nursing home placement,
and reduced care costs. The use of Amyloid-specific Positron Emission Tomogra-
phy (PET) scanning might complement routine clinical diagnostic procedures and
lead to earlier and more accurate differential diagnosis than presently possible.
The aim of this study is to estimate cost-effectiveness of Florbetaben PET imaging.
METHODS: A decision-analytic model using Markov cohorts to simulate Alzhei-
mer’s disease (AD) management compares, from a societal perspective, three strat-
egies after routine clinical assessment: 1) use of Florbetaben PET to direct treat-
ment decisions; 2) “treat all” approach; 3) “wait and see” approach. RESULTS:
Florbetaben PET appears to be cost-effective and strictly dominant: both compar-
ator strategies result in higher long-term costs at lower health outcomes. Values of
incremental costs saved (US$2340 – without considering cost of Florbetaben tracer)
and health outcomes gained (0.028 QALYs) to the nearest comparator strategy are
small. However, the results prove to be robust in sensitivity analyses.
CONCLUSIONS: Although Florbetaben PET imaging has significant upfront costs,
identifying and treating patients with AD early and correctly results in overall cost
savings and QALYs gained. This analysis may underestimate the true benefit of
Florbetaben PET imaging because the value of knowing early about the underlying
pathology from the perspective of patients and caregivers is not implemented in
the model – apart from medical and economic value, even emotional aspects and
the opportunity for future planning should be considered. This could be subject of
further research.
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WORKLOAD IN GERMAN HOSPITALS CAUSED BY ROUTINE FOLLOW-UP
SERVICES FOR CARDIAC IMPLANTABLE ELECTRICAL DEVICES (CIED)
Smala A1, Vogtmann T2
1Biotronik SE & Co KG, Global Reimbursement and Health Economics, Berlin, Germany,
2Kardiologische Gemeinschaftspraxis “Am Park Sanssouci”, Potsdam, Germany
OBJECTIVES: Regular follow-up (FU) of CIED patients is mandatory to monitor de-
vice functionality and disease status. Demand for this highly specialised service
increases continuously. However, most calendar based visits do not need further
action and could safely be replaced by remote monitoring. This model aims 1) to
quantify hospital workload associated with calendar based FU between 2011 and
2015, and 2) to identify opportunity costs if monitoring services would be per-
formed remotely. METHODS: The estimated number of prevalent CIED patients in
Germany was combined with recently published data on healthcare personnel
resource burden related to FU. Opportunity costs were identified considering 2011
DRG payments for frequent cardiology procedures. RESULTS: Assuming in-office
FU twice annually for pacemaker patients, and four times annually for implantable
cardioverter defibrillator or cardiac resynchronisation therapy patients, hospitals
will have to provide about 2.23 mio FU services in 2015, to about 856,000 patients.
These services will bind about 411,000 physician hours, 392,000 nurse hours and
280,000 technician hours, at total costs of EURO 44.8 mio to hospitals. Using remote
monitoring to replace all but one in-office FU visit per year could free up to 126,700
physician hours (2015). In theory, this physician time would allow for about 50’600
bypass surgeries (worth EURO 596 mio), or 84,400 dual-chamber pacemaker im-
plantations (EURO 434 mio), or 63,300 dual chamber ICD implantations (EURO 1.1
billion). Possible cost overestimation due to not considering unscheduled FU visits
is explored in scenario analyses. CONCLUSIONS: The ability of BIOTRONIK Home
Monitoring to safely replace in-office FU visits has been proven in clinical trials.
While continuously monitoring all patients, it is possible to identify patients in
need to attend in clinic FU in person. Remote monitoring technologies can support
hospitals with focussing their available staff and room capacities and optimise
operative income while providing patient care at potentially improved outcomes.
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PULMONARY VEIN ISOLATION FOR THE TREATMENT OF PAROXYSMAL AF:
TIME REDUCTION AND PRODUCTIVITY GAIN WITH “ANATOMICALLY-
DESIGNED” CATHETHERS COMPARED TO “POINT BY POINT” CATHETERS
Fagnani F1, Coulomb S1, Marcaud N2, Bouchet M2, Bonté J1
1Cemka, Bourg la Reine, France, 2Medtronic France SAS, Boulogne Billancourt, France
OBJECTIVES: Electrical Pulmonary Vein (PV) Isolation (PVI) is regarded as effective
treatment of Symptomatic Drug-Refractory Paroxysmal Atrial Fibrillation (PAF).
Traditionally, appropriate circumferential lesions were created point-by-point, us-
ing single tip catheters guided by navigation systems, and generally employing
radiofrequency (RF) source. “Anatomically-Designed” catheters were introduced
recently and are pre-shaped to create the appropriate lesions with a single appli-
cation on each PV. We hypothesised that the shape of these catheters is associated
with reduced procedure times and Operating Room (OR) productivity gains. In this
study, catheters employing cryo (Arctic Front, Medtronic) and duty cycled bipolar
radiofrequency (PVAC, Medtronic) energy sources were examined. METHODS: Us-
ing a chart review approach, 158 procedures were included (85 with “anatomically-
designed” catheters, 73 “point-by point”) across 7 diversified French centres. Selec-
tion criteria were used to ensure comparability of procedures. In parallel an
economic analysis was performed to estimate the budgetary impact in terms of
DRG case-mix for hospitals, resulting from potential increased OR activity.
RESULTS: Reduced procedure time was observed in six out of seven participating
centres. The difference in median times was 35 minutes (p0.0192). There was
significant variability of procedures times depending on hospital status (public or
private), the experience of electrophysiologists involved and the annual activity.
Based on the DRG casemix produced in the rythmology OR and the current tariffs,
the mean revenue for the centre was estimated between 1100€ (private) and, 400 €
(public) per hour of total OR time. CONCLUSIONS: Use of “Anatomically-Designed”
PVI Catheters has the potential to substantially reduce procedure time and in-
crease procedure capacity of rythmology labs. Shorter procedure times allow better
management of OR and treatment of more patients with potential productivity
gains to hospitals that may offset the extra cost of the new techniques.
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RESOURCE UTILISATION RELATED TO CATHETER-ASSOCIATED URINARY
TRACT INFECTIONS IN SWEDISH SPINAL INJURY PATIENTS
Bruce S1, Löfroth E1, Knutsson B2, Börstell T2, Myrén KJ1
1IMS Health, Stockholm, Sweden, 2AstraTech, Mölndal, Sweden
OBJECTIVES: To collect real-life data on costs and resource use, in order to under-
stand the economic burden and treatment patterns of urinary tract infection (UTI)
amongst people with spinal injury, who are in need of chronic, intermittent
catheterisation. METHODS: We used the CEBRxA database, which combines data
from a public claims database for the South-West region of Sweden, comprising
around 1.5 million individuals, with national Swedish registers on drug utilisation
and mortality. We identified a population of spinal injury patients (ICD-10 S14.0,
S24.0, S34.0, and T91.31) who in addition had received a diagnosis of neurogenic
bladder (ICD-10 N31*), anytime during the years 2000 to 2009. UTIs were identified
through the following ICD-10 codes: N11.0, N30*, N39.0*, N39.X*, N12.-P, and N30.-P.
A cost per UTI was calculated through considering UTI-related care contacts that
occurred within 14 days from each other (from 2005-07-01 onwards). RESULTS:We
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identified 295 spinal injury patients, with a mean age at index of 44 years, an
average follow-up time of 6 years, and of which 79% were males. For 67% of the
population we observed at least one UTI, which resulted in a care contact. Inter-
estingly, a quarter of the population used prophylactic antibiotics (J01XX05), cor-
responding to an average of 235 DDDs per year, amongst users. A majority of UTIs
were handled in primary care, while over 90% of costs were contributed by UTI-
related hospitalisations. The mean cost per UTI was 43,500 SEK, while estimates
varied considerably, with costs ranging from an average of 1,800 SEK for UTIs
handled in primary care to 177,200 SEK for inpatient care. CONCLUSIONS: In a
population of spinal injury patients, costs for catheter-associated urinary tract
infections are to a large extent driven by outlier, expensive hospitalisation. There
would be a large potential for cost savings if these hospitalisations could be
avoided.
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RESOURCE UTILISATION RELATED TO URINARY TRACT INFECTIONS IN
SWEDISH SELF-CATHETERISATION PATIENTS
Löfroth E1, Bruce S1, Knutsson B2, Börstell T2, Myrén KJ1
1IMS Health, Stockholm, Sweden, 2AstraTech, Mölndal, Sweden
OBJECTIVES: To collect real-life data on costs and resource use, in order to under-
stand the economic burden of urinary tract infection (UTI) amongst a population
who has received self- catheterisation training. METHODS: We used the CEBRxA
database, which combines data from a public claims database for the South-West
region of Sweden, comprising around 1.5 million individuals, with national Swed-
ish registers on drug utilisation and mortality. We identified a population of pa-
tients who had received self-catheterisation training anytime between 2006 and
2009(procedure code GB005). UTIs were identified through the following ICD-10
codes: N11.0, N30*, N39.0*, N39.X*, N12.-P, and N30.-P. A cost per UTI was calculated
through considering UTI-related care contacts that occurred within 14 days from
each other. RESULTS: We identified 989 patients, with a high mean age at index of
65 years, 79% males, and an average follow-up time of 1.5 years. The disease burden
of this population was mainly related to the genitourinary system, like retention of
urine, benign prostate hyperplasia, cystitis, and neurogenic bladder, although es-
sential hypertonia emerged as the third most common comorbidity. We observed
an average frequency of one UTI every two years, while around one-fifth of patients
had a yearly UTI-frequency of one or above. A majority of UTIs were handled in
primary care, while around 80% of costs were contributed by UTI-related hospitali-
sations. However, among female patients, inpatient care only contributed to 60% of
total costs. The mean cost per UTI was 10,500 SEK, while estimates varied, with
average costs ranging from 2,100 SEK in primary care, to 32,000 SEK for inpatient
care. CONCLUSIONS: Patients having received self-catheterisation training were
on average of higher age and male. UTI-related hospitalisation was a clear driver of
costs, although this effect was less pronounced for women.
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A SYSTEMATIC LITERATURE REVIEW ON THE CLINICAL AND ECONOMIC
OUTCOMES ATTRIBUTABLE TO THE USE OF HEMOSTATIC MATRIX DURING
TONSILLECTOMY AND ADENOIDECTOMY
Williams EN1, Kreuwel H2, Krishnan S2
1Marinus Consulting, LLC, Life Sciences Group, Mountain View, CA, USA, 2Baxter Healthcare,
Westlake Village, CA, USA
OBJECTIVES:Approximately 880,000 tonsillectomy/adenoidectomy procedures are
performed in the US annually. Hemostatic matrix (FLOSEAL) is used for adjunctive
hemostasis in a variety of surgeries, but the health economic rationale supporting
its application in tonsillectomy and adenoidectomy has yet to be established. A
systematic literature review was conducted in order to examine the evidence for
hemostatic matrix and to consider its value in reducing the burden of these
procedures. METHODS: Applying keywords and inclusion criteria, the PubMed,
EMBASE, and Centre for Reviews and Dissemination databases were queried for
studies published in English up to March 1, 2011. Reference lists and the American
Academy of Otolaryngology-Head and Neck Surgery database were also manually
searched. Data on costs, resource utilization, and health outcomes were extracted
and summarized. RESULTS: Four prospective, randomized controlled trials pro-
vided data on 187 patients treated with hemostatic matrix. In the two studies
utilizing crossover design, no patients in the hemostatic matrix groups required
electrocautery, whereas 3 of 35 (9%) and 4 of 34 (12%) patients, respectively, re-
quired adjunctive hemostatic matrix intraoperatively after failing electrocautery.
In all three studies measuring operating room time, use of hemostatic matrix re-
sulted in significantly shorter mean durations (range, 0.93 to 24.6 minutes) com-
pared to electrocautery (range, 9.53 to 32.6 minutes) (all studies, P0.05). Although
postoperative bleeding rates did not differ, hemostatic matrix-treated patients in
three of four studies reported significant reductions in postoperative pain scores
and narcotic consumption compared to electrocautery-treated patients (P0.05).
CONCLUSIONS: Published evidence suggests that hemostatic matrix is effective in
achieving intraoperative hemostasis during tonsillectomy/adenoidectomy. Given
the high volume of procedures, using hemostatic matrix during tonsillectomy and
adenoidectomy may be potentially cost saving due to resulting reductions in oper-
ating time and postoperative narcotic consumption. Further research may identify
patients who are more likely to benefit from hemostatic matrix in this indication.
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DATA VISUALIZATION FOR BUSINESS INTELLIGENCE: ASSESSING AN ONLINE
TOOL USED FOR BENCHMARKING HOSPITAL PROCEDURE COSTS TO
REIMBURSMENT IN CARDIAC CATHETERIZATION AND ELECTOPHYSIOLOGY
PROCEDURES
Cload P1, Mallow P2, Mako J2, Gunnarsson C3
1GE HealthCare, Chalfont St Giles, UK, 2s2 Statistical Solutions, Inc., Cincinnati, OH, USA, 3S2
Statistical Solutions, Inc., Cincinnati, OH, USA
OBJECTIVES: Data visualization as a form of business intelligence and knowledge
discovery will democratize the use of large scale payer/claims and electronic med-
ical records databases. The goal of this analysis was to assess the feasibility of
utilizing Tableau Software™ to create a data visualization tool that would augment
data mining and analytic methods for understanding hospital costs and reim-
bursement patterns in cardiac catheterization and electrophysiology procedures.
METHODS: The Premier Perspective® database was utilized for this analysis. The
Premier Perspective® database houses data from over 600 hospitals and ambula-
tory surgery centers across the United States. Eligible procedures were those that
occurred during the year 2010 with the associated ICD-9 or CPT codes for either
cardiac catheterization or electrophysiology procedures. All data were imported
into Tableau Software™ and dashboards were created to visualize the data by
procedure costs and department costs. Summary statistics of hospital utilization,
total costs, components of costs, and hospital charges for both inpatient and out-
patient settings are available for exploration in a dynamic manner by each quarter
in 2010. Each dashboard is hosted in a secure online environment and fully inter-
active allowing for dozens of different filters to be applied. RESULTS: For the year
2010 there were 1,104,936 visits of cardiac related procedures With 164,210 unique
cardiac catheterization procedures and 22,263 cardiac electrophysiology proce-
dures. Custom developed dashboards show procedures (and associated volumes)
by in- and out- patient status, by ICD-9 or CPT code, department, costs and CMS
reimbursement levels. This data visualization tool makes it possible to quickly see
hospital cost breakdowns on dozens of different dimensions. CONCLUSIONS: Tab-
leau Software™ is a powerful tool to enable the health outcomes researcher to have
insights into complex multilevel data. Business intelligence tools developed in this
manner enable visual interaction and exploration of data for rapid hypothesis
generation and business intelligence.
Medical Device/Diagnostics – Patient-Reported Outcomes & Preference-Based
Studies
PMD58
PROVISION AND FINANCING OF MEDICAL AIDS IN THE MANAGEMENT OF
RARE DISEASES: THE CASE OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Henschke C
Berlin University of Technology, Berlin, Berlin, Germany
OBJECTIVES: Patients suffering from ALS have a need for a multitude of medical
aids. Existing (bureaucratic) hurdles might create plenty of problems for people
with rare diseases. Uncertainty about provision of medical aids and substantial
waiting times limit patient’s ability to participate in the activities of daily living.
This study aims 1) to analyze problems in financing and provision of medical aids;
2) to explore differences in reimbursement decisions of private and social health
insurance (SHI); and 3) to explore patient satisfaction according to the type of
health insurance. METHODS: First, published and grey literature was used to anal-
yse payment flows and supply chain activities of the various actors involved in the
provision and payment of medical aids. Second, a survey of ALS patients (n20)
based on semi-standardized questionnaires was conducted . Gathered information
included patients’ demographic characteristics, information on coverage decisions
and problems in the provision of medical aids. Based on patient satisfaction, anal-
ysis of variance tests were performed to investigate differences in satisfaction
between SHI and privately insured persons. RESULTS: A majority of patients expe-
rienced problems in reimbursement decisions, particularly in the case of expensive
or individually customized technologies. These reimbursement problems were
more common among SHI insured persons. Both SHI insured and privately insured
persons complain about long duration processes of individual requests for meeting
the cost. Nonetheless, most patients stated that they were satisfied with the actual
provision of medical aids, including product and service quality. CONCLUSIONS:
Our results suggest that difficulties with medical aids’ reimbursement decision
processes are a common problem among SHI and private insured ALS patients.
Although the patient’s insurance type has an impact on these time-consuming
process. Consequently, there is a need for an interdisciplinary approach in the
provision of medical aids. Case managers might be a solution to overcome these
problems.
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COMPLICATED PARKINSON’S DISEASE: DISCRETE CHOICE ANALYSIS TO
ASSESS PATIENTS’ PREFERENCES. A PILOT STUDY
Lloyd AJ1, Herdman M2, Gonzalez P3
1Oxford Outcomes, an ICON plc Company, Oxford, Oxon, UK, 2Insight Consulting & Research,
Mataro, Spain, 3Medtronic Iberia, Madrid, Spain
OBJECTIVES: In advanced or complicated Parkinson’s disease (CPD), among other
treatment alternatives, patients can receive deep brain stimulation (DBS) or con-
tinuous duodenal levodopa-carbidopa infusion (CDLCI). This pilot study was de-
signed to understand the preferences of patients who face these treatment choices.
METHODS:Treatment attributes were identified based on a literature review, focus
groups with patients, caregivers, and interviews with clinicians. A discrete choice
experiment survey was developed, reviewed by clinicians and piloted with pa-
tients. Patients (potentially considering DBS or CDLCI) in Spain (n30) and the UK
(n10) completed the survey . Treatment attributes included surgery type, impact
on daily life, medication need, speech difficulties, movement control, dyskinesia,
and off-periods. Data were analyzed using a multi-level hierarchical logistic model.
RESULTS: Surgery type (DBS electric lead insertion in the brain vs CDLCI intraduo-
denal tube placement) was the most powerful predictor in the model, with a pref-
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